Akero aims to develop and deliver transformational medicines to patients with high unmet medical need. Akeroâs current focus is advancing our lead program, AKR-001, to provide a powerful new therapy for patients with NASH (non-alcoholic steatohepatitis). Akero is led by industry veterans with decades of experience delivering innovative medicines to patients. We are united in our commitment to developing transformational new therapies for NASH and other serious metabolic diseases. Source
No articles found.
Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) is a medical technology compan...
Axonics Modulation Technologies, Inc. (NASDAQ:A...
Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigene...
Epizyme, Inc. is a clinical stage biopharmaceut...
Cyndescope Inc. is a technology company focusing on software solutions for the hea...
Cyndescope Inc. is a technology company focusin...
We exist to create an alternate future for people living with neurodegenerative di...
We exist to create an alternate future for peop...
Geron is a late-stage clinical biopharmaceutical company focused on the developmen...
Geron is a late-stage clinical biopharmaceutica...
Acorda Therapeutics is a biotechnology company focused on developing therapies tha...
Acorda Therapeutics is a biotechnology company ...
Albireo is a clinical-stage biopharmaceutical company focused on the development a...
Albireo is a clinical-stage biopharmaceutical c...
Join the National Investor Network and get the latest information with your interests in mind.